SLC5A2 and Hyperglycemia: SGLT2 inhibition reduces the reabsorption of glucose and therefore enhances urinary glucose excretion, consequently decreasing both fasting and postprandial hyperglycemia and preventing glucotoxicity, and consequently hyperglycemia-induced damage.